Pharmalittle: We’re reading about Medicare and obesity drugs, GSK asthma inhalers, and more
The Congressional Budget Office forecast that Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years.”
The Congressional Budget Office forecast that Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years.”
It takes great minds with a lot of heart to find a cure for diseases like Duchenne muscular dystrophy.
The first signs that H5N1 avian flu was starting to spread from person to person would trigger a race to produce massive amounts of vaccine.
The agency simply doesn’t have enough resources to challenge but 1% of hospital mergers, so they continue to result in less competition and higher prices.
APCCC 2024 global access of advanced prostate cancer, Prostate cancer incidence, radical prostatectomy, pidemiological differences of prostate cancer between China and the United States.
APCCC 2024 how to identify aggressive variant prostate cancer, Castrate-resistant prostate cancer, aggressive variant prostate cancer, neuroendocrine prostate cancer, SPOP alterations.
APCCC 2024 promise and pitfalls of social media and artificial intelligence for prostate cancer, Lancet Commission on Prostate Cancer,
Novo Nordisk’s move to discontinue its Levemir insulin has left patients to “pick up the pieces.”
The FTC’s noncompete ban could force sweeping changes in the health care industry, but implementation of the rule will almost certainly be held up by…
APCCC 2024, alternative PSMA Ligands, 68Ga-PSMA-11, 18F-DCFPyL, 18F-PSMArh7.3, 18F-PSMA-1007, benign bone uptake, PSMA-617, PSMA-I&T, SPOTLIGHT trial, 18F-PSMArh7.33, UCLA/UCSF trial, CONDOR trial.
APCCC 2024, metastatic castration resistant prostate cancer (mCRPC), PSMA radioligand therapy, Docetaxel, cabazitaxel, 177Lu-PSMA-617, TROPIC trial, CARD trial, TAX327 trial, SWOG 9916 trial, PRESIDE trial,…